<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04563754</url>
  </required_header>
  <id_info>
    <org_study_id>H-44616</org_study_id>
    <nct_id>NCT04563754</nct_id>
  </id_info>
  <brief_title>The Effectiveness of High Resolution Microendoscopy for People Living With HIV</brief_title>
  <official_title>The Effectiveness of High Resolution Microendoscopy (HRME) in High Grade Intraepithelial Lesions (HSIL) Diagnosis for People Living With HIV</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Baylor College of Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Icahn School of Medicine at Mount Sinai</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>William Marsh Rice University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of California, San Francisco</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The University of Texas Health Science Center, Houston</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>M.D. Anderson Cancer Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Baylor College of Medicine</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators have developed a portable, battery-operated, mobile high-resolution&#xD;
      microendoscope (mHRME) that provides subcellular images of the anal epithelium, delineating&#xD;
      the cellular and morphologic changes associated with neoplasia. The investigators' central&#xD;
      hypothesis is that this 'optical' approach will increase the efficiency, clinical impact, and&#xD;
      cost-effectiveness of the current standard of HRA (High resolution anoscopy)-guided biopsy&#xD;
      thus facilitating usage by less-experienced clinicians in community-based or low-resource&#xD;
      settings. To validate this, the investigators will conduct a study to determine the&#xD;
      efficiency and diagnostic characteristics of the mHRME 'optical biopsy' approach versus the&#xD;
      current standard of HRA-based tissue biopsy. Successful results will allow for improved&#xD;
      efficacy and resource utilization for cancer screening in people living with HIV for anal&#xD;
      cancer and other epithelial cancers including the cervix, oral cavity, bladder, and GI tract.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The investigators' central hypothesis is that using mHRME plus 3D mapping as a diagnostic&#xD;
      tool will improve the accuracy and efficiency of HSIL diagnoses.&#xD;
&#xD;
      Additionally, the investigators hypothesize that the sensitivity (SN) specificity (SP),&#xD;
      positive predictive value (PPV) and negative predictive value (NPV), as well as the receiver&#xD;
      operating curve for the identification of neoplasia on a per biopsy and per patient basis&#xD;
      will be high.The investigators will first compare the HRA-directed biopsy (as the gold&#xD;
      standard) to the results of the mHRME HSIL diagnosis. The SN of mHRME diagnosis in detection&#xD;
      of HSIL will be estimated with the binomial proportion of study participants who are positive&#xD;
      for HSIL on HRA-guided biopsy at two thresholds of histology thresholds which are: 1) AIN&#xD;
      (Anal intraepithelial neoplasia) 2+ threshold, and 2) AIN3+ threshold. SP will be estimated&#xD;
      as the proportion of study participants who are negative for HSIL on HRA-guided biopsy at&#xD;
      both thresholds. Positive and negative predictive values will be estimated using the binomial&#xD;
      proportion and its 95% confidence interval (CI). In addition, the Cohens kappa statistic, and&#xD;
      receiver operator characteristic curves will be generated if patient characteristics such as&#xD;
      low CD4 count, cART (combined antiretroviral treatment) utilization, or high HIV viral load&#xD;
      impact the determination of SN and SP. SN and SP of mHRME-based HSIL diagnosis will be&#xD;
      estimated on a per lesion and per patient basis with 95% CI and compared by McNemar's test. A&#xD;
      generalized linear model for logistic regression with multiple correlated outcomes will&#xD;
      compare SN and SP of each method on a per biopsy and per patient basis.&#xD;
&#xD;
      Primary Objective To determine if the mHRME plus 3D mapping improves the accuracy of anal&#xD;
      HSIL diagnosis compared to the gold standard of histologic diagnosis of HSIL by high&#xD;
      resolution anoscopy (HRA)-guided biopsy&#xD;
&#xD;
      Secondary Objectives&#xD;
&#xD;
      Determination whether HRME changes the decision to perform biopsy&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 1, 2019</start_date>
  <completion_date type="Anticipated">November 2023</completion_date>
  <primary_completion_date type="Anticipated">December 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Screening</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Performance characteristics: Sensitivity (SN), Specificity (SP), positive predictive value (PPV) and negative predictive values (NPV)</measure>
    <time_frame>Day 1</time_frame>
    <description>The primary outcome of this study is to measure the operating characteristics including SN, SP, PPV and NPV comparing the physician- and algorithm- guided HRME-based image compared to the Lugol's- guided physician diagnosis of HSIL during HRA</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Procedure efficiency</measure>
    <time_frame>Day 1</time_frame>
    <description>Diagnostic yield: The number of neoplastic biopsies/total number of biopsies obtained in patients who received biopsies.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Procedure time</measure>
    <time_frame>Day 1</time_frame>
    <description>Change in total procedure time for HRA plus mHRME vs HRA guided biopsy</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Anal High Grade Squamous Intraepithelial Lesion</condition>
  <arm_group>
    <arm_group_label>mHRME and HRA</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>5-10 ml of proflavine hemisulfate (0.01%) will be applied on the anal epithelium. The mHRME will then be inserted and imaging of abnormal tissues will be performed.&#xD;
This is a single-arm study where all subjects will receive both standard of care HRA (High resolution anoscopy) and experimental mHRME imaging.</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>mHRME (Mobile High resolution microendoscope)</intervention_name>
    <description>SOC (standard of care) HRA with Lugol's iodine will be performed. Unstained (abnormal) area will be evaluated with mHRME for optical biopsy diagnosis: 1) contrast agent will be applied to anal epithelium (5-10 ml of proflavine hemisulfate (0.01%)).2)The mHRME will then be inserted and imaging of abnormal tissues will be performed. This will add 2 to 6 minutes per procedure.&#xD;
This is a single-arm study where all subjects will receive both standard of care HRA (High resolution anoscopy) and experimental mHRME imaging.</description>
    <arm_group_label>mHRME and HRA</arm_group_label>
    <other_name>Anoscopy</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Consentable patients with documented HIV disease&#xD;
&#xD;
          -  Either: 1) previously documented HSIL or 2) abnormal anal cytology within the past 2&#xD;
             years&#xD;
&#xD;
          -  Ages 18 years and older&#xD;
&#xD;
          -  Seen at the Baylor-affiliated Thomas Street Clinic (TSC), Mount Sinai Hospital and&#xD;
             affiliated clinics&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Unable to undergo routine anoscopy&#xD;
&#xD;
          -  Allergy or prior reaction to the fluorescent contrast agent Proflavine or Iodine&#xD;
&#xD;
          -  Unable to give informed consent&#xD;
&#xD;
          -  Current or prior history of Invasive Anal Cancer&#xD;
&#xD;
          -  Known permanent or irreversible bleeding disorder, or other hematologic disorder that&#xD;
             in the opinion of the investigator would place the patient at increased risk for&#xD;
             adverse outcome from the procedure&#xD;
&#xD;
          -  Pregnancy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sharmilla Anandasabapathy, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Baylor College of Medicine</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Elizabeth Y Chiao, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>M.D. Anderson Cancer Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Sharmilla Anandasabapathy, MD</last_name>
    <phone>7137980950</phone>
    <email>Sharmila.Anandasabapathy@bcm.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Elizabeth Y Chiao, MD</last_name>
    <phone>7137921860</phone>
    <email>eychiao@mdanderson.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Icahn School of Medicine at Mount Sinai</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10029</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Courtney Chan</last_name>
      <phone>212-241-3150</phone>
      <email>courtney.chan@mountsinai.org</email>
    </contact>
    <investigator>
      <last_name>Michael M Gaisa, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Baylor</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Zoe Wilhelm</last_name>
      <phone>713-798-7542</phone>
      <email>zwilhelm@bcm.edu</email>
    </contact>
    <contact_backup>
      <last_name>suchismita Raychaudhury</last_name>
      <phone>713-440-4624</phone>
      <email>raychaud@bcm.edu</email>
    </contact_backup>
    <investigator>
      <last_name>Elizabeth Y Chiao, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>March 10, 2020</study_first_submitted>
  <study_first_submitted_qc>September 22, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">September 24, 2020</study_first_posted>
  <last_update_submitted>September 7, 2021</last_update_submitted>
  <last_update_submitted_qc>September 7, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Baylor College of Medicine</investigator_affiliation>
    <investigator_full_name>Elizabeth Chiao</investigator_full_name>
    <investigator_title>Professor of Medicine</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Squamous Intraepithelial Lesions of the Cervix</mesh_term>
    <mesh_term>Carcinoma, Squamous Cell</mesh_term>
    <mesh_term>Carcinoma in Situ</mesh_term>
  </condition_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>September 2, 2020</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/54/NCT04563754/Prot_001.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Informed Consent Form</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>Yes</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>September 2, 2020</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/54/NCT04563754/ICF_000.pdf</document_url>
    </provided_document>
  </provided_document_section>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

